Reumatología
Complexo Hospitalario Universitario de Vigo
Vigo, EspañaPublicaciones en colaboración con investigadores/as de Complexo Hospitalario Universitario de Vigo (33)
2024
-
18F-FDG-PET/CT Scan for Detection of Large Vessel Involvement in Giant Cell Arteritis: Arteser Spanish Registry
Journal of Clinical Medicine, Vol. 13, Núm. 20
-
Diffuse alveolar hemorrhage in patients with systemic lupus erythematosus: data from the Spanish society of rheumathology Lupus Register (RELESSER)
Rheumatology International, Vol. 44, Núm. 11, pp. 2445-2455
-
Incidence and clinical manifestations of giant cell arteritis in Spain: results of the ARTESER register
RMD open, Vol. 10, Núm. 1
-
SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort
Lupus Science and Medicine, Vol. 11, Núm. 1
2023
-
Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients
Clinical and experimental rheumatology, Vol. 41, Núm. 4, pp. 829-836
-
Pregnancy outcomes in 1869 pregnancies in a large cohort from the Spanish Society of Rheumatology Lupus Register (RELESSER)
Seminars in Arthritis and Rheumatism, Vol. 61
2022
-
Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis
npj Genomic Medicine, Vol. 7, Núm. 1
-
Prevalence of symptomatic axial osteoarthritis phenotypes in Spain and associated socio-demographic, anthropometric, and lifestyle variables
Rheumatology International, Vol. 42, Núm. 6, pp. 1085-1096
-
Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients
Therapeutic Advances in Musculoskeletal Disease, Vol. 14
2021
-
Comment on: Prevalence of systemic lupus erythematosus in Spain: higher than previously reported in other countries? Reply
Rheumatology (Oxford, England), Vol. 60, Núm. 3, pp. e120-e121
-
Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?
Clinical and Experimental Rheumatology, Vol. 39, Núm. 3, pp. 555-563
-
Epidemiological Characteristics and Adverse Events of Patients with Psoriatic Arthritis Undergoing Treatment with Biological Therapies in Galicia
Reumatologia Clinica, Vol. 17, Núm. 3, pp. 150-154
-
Prevalence of symptomatic osteoarthritis in Spain: EPISER2016 study
Reumatologia Clinica, Vol. 17, Núm. 8, pp. 461-470
-
Secukinumab as Biological Treatment for Psoriatic Arthritis in Real Clinical Practice
Reumatologia Clinica, Vol. 17, Núm. 4, pp. 203-206
2020
-
A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease
Scientific Reports, Vol. 10, Núm. 1
-
Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality
Lupus, Vol. 29, Núm. 12, pp. 1556-1565
-
Efficacy and Safety of Combined Therapy With Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Systematic Literature Review
Reumatologia Clinica, Vol. 16, Núm. 5P1, pp. 324-332
-
Fracture risk assessment in the general population in Spain by FRAX® algorithm. EPISER2016 study
Medicina Clinica, Vol. 154, Núm. 5, pp. 163-170
-
Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice
Clinical and experimental rheumatology, Vol. 38, Núm. 2, pp. 112-119
2019
-
GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways
Nature Communications, Vol. 10, Núm. 1